La chaîne d'options affiche les données clés des options sur actions de Invivyd à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Invivyd..

Invivyd (NASDAQ:IVVD) Stock, Chaîne d'Options

INVIVYD INC

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

UBS analyst Douglas Harter upgrades Chimera Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>) from Neutral to Buy and raises the price target from $11.5 to $15.

News

Upgrades

Price Target

Analyst Ratings

UBS Upgrades Chimera Investment to Buy, Raises Price Target to $15

Mesa Air Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) reported $115.26 million in sales this quarter. This is a 0.78 percent increase over sales of $114.37 million the same period last year.

Earnings

MESA

Mesa Air Gr Q4 Sales $115.26M Up From $114.37M YoY

MediPharm Labs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LABS#TSX">LABS</a>) reported quarterly sales of $10.81 million which beat the analyst consensus estimate of $10.54 million by 2.52 percent. This is a 10.59 percent increase over sales of $9.77 million the same period last year.

Earnings Beats

TSX:LABS

MediPharm Labs Q1 Sales $10.81M Beat $10.54M Estimate

Scotiabank analyst Ben Isaacson downgrades Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) from Sector Outperform to Sector Perform and maintains the price target from $62 to $62.

Downgrades

Scotiabank Downgrades Nutrien to Sector Perform, Maintains Price Target to $62

TXO Partners, L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXO#NYSE">TXO</a>) ("TXO") today announced the pricing of its public offering of $175 million of our common units, made up of 11,666,667 common units representing limited partner interests in TXO (the "common units") at price to the public of $15.00 per common unit. TXO has granted the underwriters an option to purchase up to an additional 1,750,000 common units at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 15, 2025, subject to customary closing conditions.
TXO expects to receive net proceeds of approximately $165.3 million, after deducting underwriting discounts and commissions and excluding any exercise of the underwriters' option to purchase additional common units. TXO intends to use the net proceeds from this offering, if consummated, to fund a portion of the cash consideration for the previously announced asset acquisition from White Rock Energy, LLC, a portfolio company of Quantum Capital Group (the "Acquisition"). The offering is not conditioned on the consummation of the Acquisition. Pending the closing of the Acquisition, and in the event that the Acquisition is not completed, the proceeds from the offering will be used to repay the outstanding borrowings under TXO's revolving credit facility and for general partnership purposes.

Offerings

TXO Partners, L.P. Announces Pricing Of $175M Public Offering Of 11.667M Common Units At A Price Of $15/Unit

Guidance

SGBX

Safe & Green Holdings Provides Corporate Update; To Evaluate High-Value Partnerships And Acquisitions Across US Energy Production, Sustainable Technologies And Modular Construction Solutions

Today, Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) subsidiary Lockheed Martin España S.A. signed a significant industrial cooperation agreement with the Spanish Ministry of Defense, providing the Spanish defense industry with increased engineering and production capability. This agreement leads to the opportunity for Spanish Industry to compete for the production of Patriot Advanced Capability-3 (PAC-3) Missile Segment Enhancement (MSE) components. This agreement marks a major milestone in the company's efforts to strengthen defense supply chains, harnessing the best of Spanish, U.S. and greater European industry.
The agreement, signed during the International Defence and Security Exhibition of Spain, (FEINDEF) outlines a framework for future collaboration on industrial development projects in Spain with leading Spanish defense technology firms Sener and Oesía-Tecnobit. Sener will design and develop PAC-3 MSE actuators based on Lockheed Martin specifications and Oesía Tecnobit will produce specialized PAC-3 MSE cables and harnesses. Lockheed Martin España has been working closely with these companies since 2023.

Lockheed Martin Expands Industrial Cooperation In Spain With New PAC-3 MSE Agreement

Citigroup analyst Geoff Meacham upgrades Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Neutral to Buy and raises the price target from $600 to $700.

REGN

Citigroup Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $700

Saudi Arabian Mining Company ("Maaden" or the "Company", 1211 on the Saudi Exchange), one of the world's fastest growing mining companies, has signed an agreement with MP Materials Corp ("MP Materials") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), the American fully integrated rare earth producer, to explore opportunities to establish a fully integrated, end-to-end rare earth supply chain.
A Memorandum of Understanding (MoU) was signed on the sideline of the U.S.-Saudi Investment Forum 2025, taking place in Riyadh.
This agreement combines world-class exploration and processing expertise to advance and de-risk the development of potential Rare Earth Element (REE) deposits across Saudi Arabia as it continues to position itself as a world-leading player in the critical minerals sector. Maaden and MP Materials aim to explore opportunities to jointly develop a vertically integrated rare earth supply chain in Saudi Arabia, including mining, separation, refining, and magnet production, to drive industrial depth and create value for downstream sectors.
 &nbsp;
 &nbsp;

Saudi Arabian Mining Agrees With MP Materials To Explore Opportunities To Establish Fully Integrated, End-To-End Rare Earth Supply Chain

Billionaire hedge-fund boss Bill Ackman hailed Sen. Ted Cruz's proposal to give every newborn American a $1,000 investment account, posting on X: "I have been a fan of this idea for years. It is great to see it finally happening."
What Happened: Ackman's praise followed Cruz's CNBC <a href="https://www.cnbc.com/video/2025/05/13/sen-ted-cruz-on-invest-america-act-allows-kids-to-climb-the-economic-ladder-much-faster.html">clip</a> touting the Invest America Act, which the Texas Republican says will &#8220;create an investment account for every newborn American child that the federal government will seed with $1,000.&#8221; A House version surfaced Tuesday in the Ways and Means Committee's budget package, signaling the plan's first real legislative traction.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I have been a fan of this idea for years. It is great to see it finally happening. <a href="https://t.co/kdSZkrch8X">https://t.co/kdSZkrch8X</a> <a href="https://t.co/AtspxvcVE2">https://t.co/AtspxvcVE2</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1922391975002566835?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See also: <a href="https://www.benzinga.com/general/entertainment/25/05/45403511/bill-gates-predicted-in-1995-that-one-day-computers-might-think-on-their-own-but-called-it-a-scary-thought-and-admitted-no-one-knows-when-that-will-happen">Bill Gates Once Warned That Computers Might Eventually Think On Their Own—But Admitted It Was A &#8216;Scary Thought&#8217; That &#8216;No One Knows When That Will Happen&#8217;</a>
Under the bill, each account would track a low-cost S&amp;P 500 index fund. Relatives could add up to $5,000 a year, and the balance could be tapped at 18 for college, a first home or a business launch. Cruz's office estimates the nest egg could hit roughly $170,000 by adulthood, assuming a 7 percent annual return.
What To Know: Backers frame the idea as program that would broaden stock ownership and "cultivate a generation of capitalists," in Cruz's words.
Critics, as per a <a href="https://www.houstonchronicle.com/politics/texas/article/ted-cruz-tax-cut-plan-20324854.php">report</a> by the Houston Chronicle, counter that seeding every baby — about 3.6 million births a year — could cost billions and lacks income caps, raising deficit alarms. House Republicans rebranded the accounts "MAGA Savings" in their draft, reflecting former President Donald Trump's push to add pro-growth sweeteners to a broader 2017 tax-cut extension.
Even with Ackman's Wall Street clout behind it, the measure faces a steep climb in a divided Congress. But the financier's endorsement echoes a rare bipartisan appeal of giving every American a personal stake in the market from day one.
Read next: <a href="https://www.benzinga.com/25/05/45404338/wall-streets-most-accurate-analysts-spotlight-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a>

Education

Personal Finance

General

Sen. Ted Cruz Wants To Give Americans $1,000 At Birth To Invest, Bill Ackman Says He's 'Been A Fan Of This Idea For Years'

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 11.76 percent increase over losses of $(0.17) per share from the same period last year. The company reported $1.55 million in sales this quarter.

ATAI

ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M

Citigroup analyst Geoff Meacham downgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Buy to Neutral and lowers the price target from $210 to $205.

ABBV

Citigroup Downgrades AbbVie to Neutral, Lowers Price Target to $205

Earnings Outlook
The Company has raised its full-year 2025 guidance for new transaction funding outside of the Lennar Master Program to $1.5 billion, up from the previously announced $1 billion, driven by heightened demand.
Accordingly, the Company has also increased year-end quarterly earnings per share run-rate to a range of $0.69 to $0.71.

Raised Its FY25 Guidance For New Transaction Funding Outside Of The Lennar Master Program To $1.5B, Up From The Previously Announced $1B, Driven By Heightened Demand;  Increased Year-End Quarterly Earnings Per Share Run-Rate To A Range Of $0.69 To $0.71.

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4427161-1&amp;h=1470666501&amp;u=https%3A%2F%2Fatossatherapeutics.com%2F&amp;a=Atossa+Therapeutics%2C+Inc.">Atossa Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer.

ATOS

Atossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer

Millrose Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>) reported quarterly earnings of $0.39 per share.

Millrose Properties Q1 EPS $0.39

Antalpha Platform Holding Company ("Antalpha" or the "Company") today announced the pricing of its initial public offering of 3,850,000 ordinary shares at a price to the public of $12.80 per ordinary share. The ordinary shares have been approved for listing and are expected to begin trading on the Nasdaq Global Market on May 14, 2025, under the ticker symbol "ANTA." The offering is expected to close on May 15, 2025, subject to customary closing conditions.
Antalpha has granted the underwriters a 30-day option to purchase an additional 577,500 ordinary shares to cover over-allotments in connection with the offering.

IPOs

ANTA

Antalpha Announces Pricing Of Initial Public Offering Of 3.85M Shares At A Price Of $12.80 Per Share

Citigroup analyst Arthur Truslove downgrades UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) from Buy to Neutral and raises the price target from $60.5 to $71.

Citigroup Downgrades UL Solutions to Neutral, Raises Price Target to $71

IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year.

IOBT

IO Biotech Q1 EPS $(0.34) Beats $(0.38) Estimate

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Shutterstock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.83%</li>
<li>JMP Securities analyst Andrew Boone reiterated a Market Perform rating on May 5, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Needham analyst Bernie McTernan maintained a Buy rating and cut the price target from $45 to $30 on March 7, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 2, the company posted downbeat quarterly results</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">SSTK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="896" height="811" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png" alt="" class="wp-image-914631" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png 896w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-768x695.png 768w" sizes="(max-width: 896px) 100vw, 896px" /></a></figure>
<h3 class="wp-block-heading">Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.35%</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $55 to $56 on April 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Scotiabank analyst Maher Yaghi maintained a Sector Perform rating and increased the price target from $48.5 to $49 on April 23, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On May 13, Verizon announced a $5 billion commitment to continue investing in America and supporting small businesses.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">latest VZ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="907" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png" alt="" class="wp-image-914632" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-768x709.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.27%</li>
<li>Benchmark analyst Daniel Kurnos maintained a Buy rating and raised the price target from $215 to $220 on May 9, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Overweight rating and cut the price target from $216 to $200 on May 1, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 8, Nexstar Media Group reported better-than-expected first-quarter EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NXST <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="895" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png" alt="" class="wp-image-914635" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-768x709.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

NXST

SSTK

Wall Street's Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) affirms FY2025 sales outlook from $30.00 million to $30.00 million vs $40.20 million estimate.

ALUR

Allurion Technologies Affirms FY2025 Sales Guidance of $30.00M vs $40.20M Est

Press Releases

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Health Care

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Management

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Financing

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Comments

Invivyd

Invivyd (IVVD) Options

Invivyd (NASDAQ:IVVD) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL